HelioLiver™ LDT · A Simple Blood Test for Liver Cancer
Saving Lives by Detecting Cancer Early
At Helio, we're on a mission to save lives. HelioLiver™ is a simple blood test for the early detection of liver cancer (HCC), helping physicians detect cancer earlier, when treatment has the greatest chance of success.
Validated in the CLiMB trial
Published in the Journal of Hepatology
90%
survival when cancer is
caught at an early stage
caught at an early stage
4×
more Stage I cancers
detected vs. ultrasound
detected vs. ultrasound
HelioLiver™ · A simple blood test for liver cancer
HelioLiver™ LDT
A simple blood test for the early detection of liver cancer (HCC), now available through Quest Diagnostics.
Our Mission
Finding Cancer Early Is the Key to Defeating It
For the majority of cancers, 90% of people survive if their cancer is detected at an early stage. But many of today's diagnostics are inconvenient, expensive, and poor predictors of early-stage cancer.
Now with Helio, finding cancer early is as simple as a blood draw. We focus our work on early detection, when treatment is most effective, and the chances of beating cancer are highest.
5-Year Survival by Stage at Detection
Majority of cancers
Detected early stage
90%
Detected late stage
21%
4× higher
Catching cancer early can quadruple the chance of survival. Source: SEER Database.
Our First Commercial Test
Detect Liver Cancer Earlier Than Ever Before
HelioLiver™ LDT is the first test built on the Helio platform, available for clinical use today. In the CLiMB trial, this groundbreaking blood test detected early-stage (T1) liver cancer four times more often than ultrasound. By combining cell-free DNA methylation with protein tumour markers and clinical data, it catches HCC when tumours are still small and curative options remain.
40% vs 10%
Stage I HCC detection, HelioLiver vs ultrasound
29% vs 0%
sensitivity for lesions under 2 cm
10–14 days
average turnaround time
Validated in the CLiMB trial and published in the Journal of Hepatology, May 2026. Now available to order through Quest Diagnostics.
The Helio Platform
One Platform. A Smarter Way to Detect Cancer.
HelioLiver is the first test built on Helio's broader AI-powered platform, which reads cell-free DNA methylation patterns to detect cancer early, and is designed to do more than detect a single disease.
Early Detection
We read proprietary methylation patterns in cell-free DNA that can reveal cancer as early as Stage I from a simple blood draw, when treatment works best.
Disease Monitoring
Beyond detection, our platform is designed to monitor minimal residual disease, helping clinicians track response and guide decisions over time.
Powered by AI
Machine learning turns complex biomarker data into clear, reliable answers, built on proprietary, patented science developed over nearly a decade.
The Science & Proof
Backed by Nearly a Decade of Peer-Reviewed Science
Since 2016, Helio Genomics has pioneered the use of DNA methylation for early cancer detection, with foundational research published in some of the world's most respected scientific journals.
2016
Founded with a proprietary, patented methylation profile of novel cancer biomarkers
2017
Early methylation detection research was published in Nature Materials and PNAS
2021
An AI and machine learning detection method was published in Nature Communications
2026
CLiMB trial results published in the Journal of Hepatology
Why It Matters
Timing Matters. Early Detection Can Lead to Better Outcomes.
Fewer than half of all liver cancers in the US are diagnosed at an early stage, while the disease is still localised. Early detection significantly improves outcomes, allowing for a higher survival rate and opening the door to potentially curative treatment options, such as surgery and transplant.
Five-year relative survival falls from localised (early-stage) to distant (advanced-stage) liver cancer · SEER Database
Partners & Recognition
We Collaborate with Leaders in Clinical Care
Bringing this groundbreaking work to patients takes partnership. Helio Genomics collaborates with leaders in clinical care and technology to expand access to early testing, including clinical availability through Quest Diagnostics, one of the largest diagnostic networks in the United States, and a strategic commercial partnership with Syneos Health. Helio Genomics also participates in the Rural Health Transformation Collaborative, a Microsoft-co-chaired initiative expanding access to earlier liver cancer detection in underserved communities.
Rural Health Transformation CollaborativeCo-chaired by Microsoft
For Every Audience
Find Your Path
For Healthcare Providers
Bring earlier cancer detection into your practice with a simple blood draw.
For ProvidersFor Patients
If you are at higher risk for liver cancer, learn how a simple blood test could help find it earlier.
For PatientsFor Investors & Partners
Explore the platform, the science, and the momentum behind Helio Genomics.
Investor Relations